Chronic lymphocytic leukaemia

Abstract

The dominating clinical presentations concerning CLL at this year's ASH meeting were given on the results of two large randomized phase III trials exploring the use of rituximab (R) in addition to fludarabine and cyclophosphamide (FC). The data of these trials as well as a phase II trial applying R-Bendamustin convincingly demonstrated the clinical benefit of chemoimmunotherapy in CLL, at least for the younger and physically fit patients without del17p. © 2009 Springer.